Real-world data provide a CARbon copy for ide-cel
In this issue of Blood, Sidana et al report the largest real-world analysis of chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma (MM), c
Related Articles
Sequential BCMA CAR-T Cell Therapy in Refractory Multiple Myeloma
Key Points. Sequential treatment with commercially available BCMA-directed CAR-T therapy in refractory myeloma is safe and efficaciousDuration of response
Real-world data provide a CARbon copy for ide-cel
In this issue of Blood, Sidana et al report the largest real-world analysis of chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma (MM), c
ASH Clinical News Seeks Associate Editors for 2026-2028 Terms | ASH Clinical News | American Society of Hematology
The American Society of Hematology (ASH) is in search of Associate Editors to join ASH Clinical News, the Society’s monthly news magazine for the broader…
Reshaping the TME to enhance checkpoint blockade in ENKTL
In this issue of Blood, Kim et al1 present compelling findings from a phase 2 trial exploring the combination of cemiplimab, an anti–programmed death-1 (an
From CyBorD to Dara-CyBorD: ASCT Utilization Trends in AL Amyloidosis, A 15-Year Analysis
Key Points. ASCT for AL amyloidosis decreased significantly (71% average annual reduction) with the introduction of Dara-CyBorDASCT now targets patients wi
Efficacy and Safety of BCMA Nanobody CAR-T Cell Therapy in Relapsed or Refractory Plasma Cell Myeloma
Key Points. Dual nanobody VHHs (dVHHs) targeting BCMA, achieved a high ORR in the treatment of relapsed or refractory plasma cell myeloma patients.Its effi
